Genetic Signatures

49 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 30 Note 3: Financial Reporting Segments (continued) Geographic locations Asia Pacific The Group’s head office and manufacturing operation is based in Sydney, Australia. 79% of the revenue was generated within the Australian entity. EMEA This business comprises Eastern and Western Europe, Middle East including Israel, and Africa. The Group is represented by employees in UK and Germany. Americas The Group’s North American business includes the United States and Canada. The Group proposes to sell products in this region and is currently having its products evaluated by the US FDA. Operations are currently based in California, USA. Asia Pacific EMEA Americas Total Consolidated - 2021 $’000s $’000s $’000s Segment revenue 25,397 4,447 1,679 31,523 Intersegment sales (3,152) (21) (66) (3,239) Total sales from external customers 22,245 4,426 1,613 28,284 Other revenue - - - - Segment revenue from external customers 22,245 4,426 1,613 28,284 Segment result from external customers 9,948 1,541 (457) 3,032 Unallocated revenue less unallocated expenses (1,276) Profit before income tax 1,756 Income tax - Net profit after tax 1,756 Consolidated - 2020 Segment revenue 10,153 1,107 3 11,263 Intersegment sales - - - - Total sales from external customers 10,153 1,107 3 11,263 Other revenue 2,554 - - 2,554 Segment revenue from external customers 12,707 1,107 3 13,817 Segment result from external customers 23 (515) (952) (1,444) Unallocated revenue less unallocated expenses (642) Loss before income tax (2,086) Income tax - Net loss after tax (2,086 ) Notes to the Financial Statements for the financial year ended 30 June 2021